Mirum Pharmaceuticals, Inc.

Hello and welcome to Miriam Pharmaceuticals' first quarter business update. My name is Harry and I'll be coordinating your call today. If you'd like to ask a question during the Q&A session, you may do so by pressing star followed by one on your telephone keypad. It is now my pleasure to hand you over to Ian Clements, Miriam's Chief Financial Officer, to begin. Mr. Clements, please go ahead.

Thanks, Harry, and good morning, everyone. I'd like to welcome you to Miriam Pharmaceuticals' first quarter 2022 conference call. I'm joined today by our President and CEO, Chris Peets, our Chief Operating Officer, Peter Radovich, and our Head of R&D, Pam Vick. Earlier this morning, Mirim issued a news release announcing the company's results for the first quarter of 2022. Copies of this news release and SEC filings can be found in the Investors section of our website. Before we begin, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements about Mirim and our programs based on management's current expectations, including statements regarding Miriam's business plans, development programs, strategies, prospects, market opportunities, and financial forecasts and guidance. Miriam is under no duty to update these statements, and they are subject to numerous risks and uncertainties, and actual results could differ materially from the results anticipated by these statements. Investors should read the risk factors set forth in MIRM's 10-K for the year ended December 31st, 2021, and any subsequent reports filed with the SEC. With all of that said, I'd like to turn the call over to Chris Peaks. Chris?

Thanks, Ian. And good morning, everyone. The first quarter of 2022 was another strong one for MIRM. In the first quarter, we achieved nearly $13 million of revenue. including nearly $11 million in net sales of Live Marley, a testament to our team's expertise and execution. The exciting pace of building value has existed at Miriam since inception, and we expect it to continue in the years ahead. We'll keep our call brief today with a quick launch and business update, and then take questions. First, for the context of the launch, I'll remind you of the heavy burden of disease and pruritus and algeal syndrome. and the tremendous impact of Livmarly seen in our clinical program. Our launch has been informed by broad clinical experience spanning many years showing durable improvements in pruritus. More recent data have evaluated the long-term impact of Livmarly, suggesting potential improvement in event-free survival over time in allogeal syndrome. The success of our launch has been underpinned by the urgency we see to bring Livmarly to patients. The importance of Live Marley to this community is evident in our commercial launch achievement in the first quarter, namely net product revenue of $10.9 million, continuing to show the progress of our commercial efforts. Our first quarter performance gives us confidence in continued growth throughout the year. And the Live Marley opportunity for cholestatic pruritus and algeal syndrome is only the beginning of what's possible for Miriam. The foundation of our pipeline and Miriam's success is innovative research for rare disease to bring new medicines to patients as quickly as possible. As we continue to execute against the greater than $500 million U.S. market opportunity in Al-Jil syndrome, we are progressing our five other late-stage Litmarli and Belixibat clinical programs, which will generate multiple data readouts over the next two years. While in parallel, we are progressing expansion in global markets of Live Marley for Allergy Syndrome. Now, with that, I'll turn it over to Peter, who will provide an update on our Live Marley launch progress.